OncoMed Pharmaceuticals, Inc. Initiates Phase 1b/2 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-59R5 (Anti-Notch2/3) in Small Cell Lung Cancer (SCLC) and Amends Phase1b/2 Pancreatic Cancer Trial
5/15/2013 10:32:30 AM
More...
|
OncoMed Pharmaceuticals, Inc. Presents New Data in Six Anti-Cancer Stem Cell Programs at American Association for Cancer Research
4/10/2013 6:12:21 AM
More...
|
FDA Clears OncoMed Pharmaceuticals, Inc.'s Demcizumab (Anti-DLL4) to Resume Clinical Testing in the U.S.
1/3/2013 9:54:09 AM
More...
|
OncoMed Pharmaceuticals, Inc. Initiates Phase 1 Clinical Trial of Anti-Cancer Stem Cell Therapeutic OMP-52M51 (Anti-Notch1)
12/21/2012 9:04:34 AM
More...
|
OncoMed Pharmaceuticals, Inc. Announces Presentations of Anti-Notch2/3 and Demcizumab Clinical Data at European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Meeting
11/9/2012 11:21:44 AM
More...
|
MorphoSys AG's Partner OncoMed Pharmaceuticals, Inc. Advances the HuCAL Antibody OMP-59R5 Into Phase 1b/2 Clinical Trial in Pancreatic Cancer
10/5/2012 9:36:48 AM
More...
|
OncoMed Pharmaceuticals, Inc. Advances Two Notch Pathway Product Candidates in Clinical Development
10/4/2012 10:08:50 AM
More...
|
Clinical Cancer Research Publishes OncoMed Pharmaceuticals, Inc. Data Demonstrating Anti-Cancer Activity for Anti-DLL4 (Demcizumab) in Pancreatic Cancer
9/6/2012 10:09:49 AM
More...
|
MorphoSys AG Partner OncoMed Pharmaceuticals, Inc. Publishes Data on HuCAL Antibody OMP-18R5
7/5/2012 8:39:15 AM
More...
|
OncoMed Pharmaceuticals, Inc. Files for $115 Million IPO
5/14/2012 7:33:48 AM
More...
|
|